Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/16299
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTomic-Smiljanic M.-
dc.contributor.authorVasiljevic, Dragan-
dc.contributor.authorTomic Lucic, Aleksandra-
dc.contributor.authorAnđelković, Nebojša-
dc.contributor.authorJakovljevic, Vladimir-
dc.contributor.authorBolovich S.-
dc.contributor.authorVeselinovic, Mirjana-
dc.date.accessioned2023-02-08T16:54:57Z-
dc.date.available2023-02-08T16:54:57Z-
dc.date.issued2019-
dc.identifier.issn0770-3198-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/16299-
dc.description.abstractIntroduction: Long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs; eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) have been reported to reduce platelet aggregation. Our aim was to prospectively assess the potential influence of different supplementation omega-3 PUFA on the antiplatelet effects in rheumatoid arthritis (RA) patients. Methods: The study included 60 patients with RA at the Department of Rheumatology, Clinical Center Kragujevac. Patients were divided into three groups depending on who used concentrated fish oil only or concentrated fish oil in combination with evening primrose oil or control group without supplementation in a period of 3 months. Platelet aggregation was measured using the multiplate analyzer and expressed through the value of adenosine diphosphate (ADP) test, aranchidonic acid–induced aggregation (ASPI) test, thrombin receptor–activating peptide (TRAP) test (to assess baseline platelet aggregation), and the ratio of ADP/TRAP and ASPI/TRAP representing the degree of inhibition of platelet aggregation compared to the basal value. The platelet function analysis in whole blood was performed 18–24 h before starting supplementation and after 90 days. Considerations were taken in the representation of demographic, clinical characteristics, and laboratory parameters between the groups. Results: Patients who used concentrated fish oil only had a significantly lower value of the ratio of ADP/TRAP (0.68 ± 0.20) compared to patients without supplementation (0.83 ± 0.12; p = 0.008), while there was no statistically significant difference in values of other laboratory parameters of platelet function between other groups. Conclusions: Co-administration of supplementation-concentrated fish oil may reduce platelet aggregation in adults with RA. Key Points: • Omega-3 PUFAs are essential for health and are known to possess anti-inflammatory properties, improving cardiovascular health as well as benefiting inflammatory diseases. • In this paper, we report on anti-aggregation effects n-3 PUFAs and ɤ-linolenic acid in RA. • The risk of cardiovascular morbidity and mortality is increased in RA, and dietary supplementation of n-3 PUFA may have preventive potential for the cardiovascular management in rheumatoid arthritis.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceClinical Rheumatology-
dc.titleInfluence of different supplementation on platelet aggregation in patients with rheumatoid arthritis-
dc.typearticle-
dc.identifier.doi10.1007/s10067-019-04569-3-
dc.identifier.scopus2-s2.0-85065658404-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

363

Downloads(s)

6

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.